Search results
Ryvu Therapeutics to present clinical and preclinical data on RVU120 at the 2024 European Hematology...
FOX 23 News Albany· 2 days agoUpdated data from the Phase I trial of RVU120 in patients with relapsed/refractory acute myeloid ...
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 1 day agoPRESS RELEASE AB SCIENCE PRESENTS ITS FINANCIAL INFORMATION AS OF DECEMBER 31, 2023 AND THE KEY EVENTS OF THE PERIOD Clinical development Continuation of the conditional marketing authorisation application procedures with
Actinium Announces Multiple Abstracts Highlighting its Antibody Radiation Conjugates Iomab-B and...
WJTV Jackson· 3 days agoIomab-B and Actimab-A are the only targeted radiotherapies in development for patients with relapsed/refractory acute myeloid leukemia
Actinium Announces Oral Presentation Detailing Improved Survival Outcomes in TP53 Positive Patients...
FOX 4 Kansas City· 2 days agoThe Phase 3 SIERRA trial enrolled 153 patients ages 55 and above with active relapsed or refractory acute myeloid leukemia (r/r AML) ...
EHA 2024 | Results from Five Studies of Ascentage Pharma's Key Drug Candidates Selected for...
WRBL Columbus· 20 hours agoAscentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that the ...
Earnings call: Bio-Path Holdings reports promising Q1 2024 results By Investing.com
Investing.com· 1 day agoBio-Path Holdings (NASDAQ: NASDAQ:BPTH), a biotechnology company focused on developing therapeutic...
Small Business - Austin Daily Herald | Austin Daily Herald
Austin Daily Herald· 3 days agoAML is a cancer of the blood and bone marrow and is the most common type of acute leukemia in adults. SENTI-202, a potential first-in-class Logic Gated ...
Opinion | Ending Oncology's Toxic Relationship With High Chemotherapy Doses
MedPage Today· 7 days agoMany years ago, my patient, a woman in her fifties with chronic myeloid leukemia (CML), got her...
Celularity Inc. (NASDAQ:CELUW) Short Interest Up 34.4% in April
ETF DAILY NEWS· 2 days agoCelularity Inc. (NASDAQ:CELUW – Get Free Report) was the recipient of a significant increase in short interest in the month of April. As of April 30th, there was short interest totalling 161,700 ...
Curis to Present Updated Data from the TakeAim Leukemia Study
WPRI Providence· 6 days ago(NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will present ...